Venus Remedies Gets Marketing Approval From Saudi Arabia For Chemotherapy Drug Docetaxel

Venus Remedies Ltd announced this week that it has received marketing authorization from Saudi Arabia for Docetaxel, a commonly used chemotherapy drug. The announcement comes three months after the company received Saudi Food and Drug Authority (SFDA) certification for all of its production facilities at its Baddi, Himachal Pradesh, unit. The company said in a statement that demand for Docetaxel has been steadily increasing around the world due to the rising incidence of breast, prostate, stomach, and non-small cell lung cancers, for which this chemotherapy drug is used as a first line of treatment.

Docetaxel-based treatment has particularly improved the survival rate among men in castration-sensitive prostate cancers, it said. The $ 102-billion global Docetaxel market is projected to grow to $ 184 billion by 2030 at a CAGR of 10.22 per cent, it added. "This approval will enable us to solidify our existing foothold in the GCC and Middle East and North Africa (MENA) regions by streamlining the registration process for our oncology drugs there, ultimately benefiting a large population in need of advanced cancer treatments," said Saransh Chaudhary, President, Global Critical Care, Venus Remedies.